Centricity Vision Revenue and Competitors
Estimated Revenue & Valuation
- Centricity Vision's estimated annual revenue is currently $3.6M per year.
- Centricity Vision's estimated revenue per employee is $125,500
Employee Data
- Centricity Vision has 29 Employees.
- Centricity Vision grew their employee count by 4% last year.
Centricity Vision's People
Name | Title | Email/Phone |
---|
Centricity Vision Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Centricity Vision?
Centricity Vision has developed a medical device, ZEPTO® , that is a disposable capsulotomy device. It creates a precise, circular capsulotomy during cataract surgery, with excellent visual axis centration. We are committed to providing high quality, automated capsulotomy devices that will become the standard of care for this procedure. We pursue innovation in all aspects of development and manufacturing to ensure we are providing the highest level of product quality, delivery and service.
keywords:N/AN/A
Total Funding
29
Number of Employees
$3.6M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Centricity Vision News
... Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) and Zepto (Centricity Vision) have helped him do just that.
Centricity Vision Announces New Technologies Under Development, ZEPTOLINK and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&D...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5M | 29 | -3% | N/A |
#2 | $4.9M | 29 | 7% | N/A |
#3 | $5.2M | 29 | 0% | N/A |
#4 | N/A | 29 | 0% | N/A |
#5 | $3M | 29 | -3% | N/A |